

Supplemental Table 1. Susceptibility results for each *A. baumannii* isolate (n=32) included in the study evaluating G3KL against standard antibiotics

Strain	Country, year	Profile ^a	Carbapenemase detected	MICs [µg/ml]																MBCs [µg/ml]		
				PTC S≤16	TIM S≤16	CAZ S≤8	FEP S≤8	ATM NA	IMP S≤2	MEM S≤2	DOR S≤2	AK S≤16	GEN S≤4	CIP S≤1	SXT S≤2	TIG NA	COL S≤2	POL S≤2	G3KL ^{b,c} Polystyrene	G3KL ^{b,c} Polypropylene	G3KL ^{b,c} Polystyrene	G3KL ^{b,c} Polypropylene
2203591	CH, 2013	-	None	≤8	≤16	1	≤2	16	≤1	≤1	0.25	≤4	≤1	≤0.25	≤0.5	≤0.25	≤0.25	≤0.25	4	4	8	8
2303905	CH, 2014	-	None	≤8	≤16	2	≤2	16	≤1	≤1	0.25	≤4	2	≤0.25	≤0.5	≤0.25	≤0.25	≤0.25	4	4	4	4
2310924	CH, 2014	MDR	None	64	128	≥32	16	≥32	≤1	2	1	≤4	≥16	≥4	≥8	0.5	1	2	8	8	8	8
C07-031	ITA, 2008	MDR	OXA-58	≥128	64	≥32	8	≥32	≤1	≤1	2	≥64	≥16	2	≥8	1	1	0.5	8	8	8	8
C12-187	ITA, 2008	MDR	OXA-58	≥128	≥256	≥32	16	≥32	≥16	8	≥4	≥64	≥16	≥4	≥8	1	0.5	0.5	4	8	4	8
C14-1315	ITA, 2008	MDR	OXA-58	64	≥256	≥32	8	≥32	8	4	≥4	≥64	≥16	≥4	4	≤0.25	0.5	1	8	8	8	8
C15-035	ITA, 2008	MDR	OXA-58	16	≥256	≥32	16	≥32	≤1	4	2	≥64	≥16	≥4	≥8	2	1	0.5	8	4	8	4
2266064	CH, 2014	XDR	None	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	4	0.5	8	8	8	8
2327362	CH, 2014	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	0.5	≤0.25	4	4	4	4
2318355	CH, 2014	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	0.5	≤0.25	16	8	16	8
2319515	CH, 2014	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	0.5	≤0.25	8	8	8	8
2317747	CH, 2014	XDR	OXA-24	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	1	2	8	4	8	4
2343324	CH, 2014	XDR	OXA-24	≥128	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	0.5	0.5	8	8	8	8
2316948-2	CH, 2014	XDR	OXA-24	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	1	0.5	8	8	8	8
2316948-1	CH, 2014	XDR	OXA-24	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	0.5	≤0.25	8	8	8	8
2332122	CH, 2014	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	0.5	0.5	8	8	8	8
2321336	CH, 2014	XDR	OXA-24	≥128	≥256	≥32	≥32	≥32	≥16	≥16	2	≥64	≥16	≥4	≥8	4	1	4	4	4	4	4
VA-645/00 ^d	ITA, 2000	XDR	OXA-24	≥128	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	0.5	≤0.25	8	8	8	8
C06-397	ITA, 2008	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	16	≥16	≥4	≥8	4	0.5	≤0.25	8	8	8	8
C13-279	ITA, 2008	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	0.5	0.5	4	8	4	8
C13-373	ITA, 2008	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	0.5	≥8	8	8	8	8
C07-007	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	≥16	2	≥8	2	1	0.5	8	8	8	8
C07-025	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	2	≥8	1	1	1	8	8	8	8
C15-207	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	1	0.5	4	4	4	4
C10-230	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	8	≥32	≥16	8	≥4	≥64	≥16	≥4	≥8	1	1	0.5	8	8	8	8
C14-275	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	8	≥32	≥16	8	≥4	16	≥16	≥4	≥8	1	1	1	8	8	8	8
C14-336	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	8	≥32	8	8	≥4	≥64	≥16	≥4	4	0.5	≤0.25	0.5	8	8	8	8
C14-1275	ITA, 2008	XDR	OXA-58	≥128	≥256	≥32	8	≥32	≥16	8	≥4	≥64	≥16	≥4	≥8	1	1	1	8	4	8	4
02C03	ITA, 2011	XDR	OXA-23	≥128	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	0.5	0.5	0.5	8	8	8	8
03C03	ITA, 2011	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	1	≤0.25	0.5	8	8	8	8
03C10	ITA, 2011	XDR	OXA-23	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	16	≥16	≥4	1	4	≤0.25	≤0.25	8	8	8	8
2172421	CH, 2013	PDR	OXA-24	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	2	≥8	≥8	8	4	8	4

Note. ID, species identification; MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; PDR, pandrug-resistant; XDR, extensively-drug resistant; MDR, multidrug-resistant; -, non-MDR; S, susceptible (according to CLSI 2014); CH, Switzerland; ITA, Italy; NA, not available; PTC, piperacillin/tazobactam; TIM, ticarcillin/clavulanate; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IMP, imipenem; MEM, meropenem; DOR, doripenem; AK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; TIG, tigecycline; COL, colistin; POL, polymyxin B.

^a According to the criteria of Magiorakos *et al.* *Clin Microbiol Infect* 18:268-281, 2012

^b Phenotypic test for G3KL were performed using polypropylene (standard) and polystyrene 96-well plates

^c Overall, 31 out of 32 strains tested with both polypropylene or polystyrene plates had the same MIC and MBC values

^d Isolate VA-645/00 was previously studied and published with the name VA-566/00 (D'Andrea *et al.*, 2009, *Antimicrob Agents Chemother* 53:3528-3533)

Supplemental Table 2. Susceptibility results for each *P. aeruginosa* (n=35) included in the study evaluating G3KL against standard antibiotics

Strain	Country, year	Profile ^a	Carbapenemase detected	MICs [µg/ml]																	MBCs [µg/ml]	
				PTC S≤16	TIM S≤16	CAZ S≤8	FEP S≤8	ATM S≤8	IMP S≤2	MEM S≤2	DOR S≤2	AK S≤16	GEN S≤4	CIP S≤1	SXT NA	TIG NA	COL S≤2	POL S≤2	G3KL ^{b,c} Polystyrene	G3KL ^{b,c} Polypropylene	G3KL ^{b,c} Polystyrene	G3KL ^{b,c} Polypropylene
2226680	CH, 2013	-	None	≤8	≤16	≤1	≤2	≤2	≤1	≤1	≤0.125	16	≥16	0.5	≤0.5	2	≥8	≥8	8	4	16	4
2184627	CH, 2013	-	None	≤8	32	16	4	8	≤1	≤1	0.25	≤4	≤1	≤0.25	4	4	1	1	8	8	8	8
2296294	CH, 2014	-	None	≤8	≤16	≤1	≤2	8	≤1	≤1	0.25	≤4	≤1	≤0.25	≥8	8	2	1	4	8	8	8
2291604	CH, 2014	-	None	16	≤16	4	4	≥32	≤1	≤1	≤0.125	≥64	2	1	4	4	2	1	16	16	32	16
2306440	CH, 2014	-	None	≤8	32	2	≤2	16	≤1	≤1	≤0.125	≤4	2	≤0.25	4	8	1	2	8	8	8	8
2307544	CH, 2014	-	None	≤8	32	≤1	≤2	8	≤1	≤1	≤0.125	≤4	≤1	≤0.25	≥8	4	1	1	4	8	4	8
2223278	CH, 2013	MDR	None	≤8	64	16	≥32	≥32	2	2	1	≤4	≤1	2	≥8	8	4	1	8	8	16	8
2186565	CH, 2013	MDR	None	≤8	32	2	≤2	≥32	≤1	≤1	0.25	≥64	≤1	≤0.25	≥8	8	≥8	≥8	4	8	8	8
2267476	CH, 2014	MDR	None	≥128	≥256	≥32	8	≥32	≥16	≥16	≥4	≥64	≤1	1	≥8	≥16	1	1	4	4	8	4
2280037-II	CH, 2014	MDR	None	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≤4	≤1	≤0.25	≥8	2	0.5	1	4	4	4	4
2280037-III	CH, 2014	MDR	None	≥128	≥256	8	16	≥32	≥16	≥16	≥4	8	4	0.5	≥8	8	1	1	4	4	8	8
VA-182/00	ITA, 2000	MDR	VIM-2	32	≥256	16	8	8	≥16	≥16	≥4	8	≥16	≥4	≥8	≥16	2	1	4	8	16	8
C02-387	ITA, 2008	MDR	VIM-type	≥128	≥256	≥32	≥32	8	≥16	≥16	≥4	16	≥16	≥4	≥8	8	1	1	8	8	8	8
C20-111	ITA, 2008	MDR	IMP-type	16	≥256	≥32	≥32	≥32	2	2	1	≤4	≥16	≥4	≥8	≥16	1	1	8	4	8	4
2280037-I	CH, 2014	XDR	None	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	4	0.5	4	≥16	≥8	≥8	8	8	8	8
2256279	CH, 2014	XDR	None	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	2	4	0.5	1	4	8	4	8
VA-506/99	ITA, 1999	XDR	IMP-2	≥128	128	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	8	2	1	4	8	8	8
C08-053	ITA, 2008	XDR	IMP-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	8	≥16	≥4	≥8	≥16	2	1	8	8	8	8
C02-072	ITA, 2008	XDR	VIM-type	64	≥256	≥32	16	16	≥16	≥16	≥4	32	4	≥4	≥8	8	2	1	8	8	8	8
C02-290	ITA, 2008	XDR	VIM-type	32	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	2	≥4	≥8	8	2	4	8	32	8	32
C02-322	ITA, 2008	XDR	VIM-type	32	≥256	16	16	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	≥16	2	1	8	8	8	8
C03-150	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	16	≥16	≥16	≥4	8	≥16	≥4	≥8	8	2	1	8	8	8	8
C05-230	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	8	≥16	≥4	≥8	8	2	1	8	8	8	8
C06-242	ITA, 2008	XDR	VIM-type	32	≥256	≥32	16	≥32	≥16	8	≥4	32	≥16	≥4	≥8	≥16	≥8	1	4	8	8	8
C06-319	ITA, 2008	XDR	VIM-type	32	≥256	16	16	≥32	≥16	8	≥4	≥64	4	≥4	≥8	8	2	1	4	8	4	8
C07-211	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	8	≥16	≥4	≥8	8	2	1	4	8	8	8
C08-035	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	8	≥16	≥4	≥8	8	2	1	4	8	8	8
C09-217	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	8	8	≥4	≤4	≥16	≥4	≥8	8	1	1	8	8	8	8
C13-395	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	16	≥32	≥16	≥16	≥4	≥64	4	≥4	≥8	≥16	1	1	4	8	8	8
C14-157	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	≥16	2	1	4	8	8	8
C17-318	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	≥16	2	1	8	8	8	8
C20-129	ITA, 2008	XDR	VIM-type	≥128	≥256	≥32	≥32	≥32	≥16	≥16	≥4	≥64	≥16	≥4	≥8	≥16	2	1	8	8	8	8
Control	USA, NA	XDR	VIM-1	≥128	≥256	≥32	≥32	16	≥16	≥16	≥4	≤4	≥16	≥4	≥8	≥16	2	1	4	4	4	4
2221712	CH, 2013	PDR	None	64	128	≥32	≥32	≥32	≥16	8	≥4	≥64	≥16	2	≤0.5	2	≥8	≥8	64	2	128	32
C05-032	ITA, 2008	PDR	VIM-type	≥128	≥256	≥32	≥32	16	≥16	≥16	≥4	32	≥16	≥4	≥8	8	≥8	≥8	8	32	8	32

Note. ID, species identification; MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; CH, Switzerland; ITA, Italy; PDR, pandrug-resistant; XDR, extensively-drug resistant; MDR, multidrug-resistant; -, non-MDR; S, susceptible (according to CLSI 2014); NA, not available; PTC, piperacillin/tazobactam; TIM, ticarcillin/clavulanate; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IMP, imipenem; MEM, meropenem; DOR, doripenem; AK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; TIG, tigecycline; COL, colistin; POL, polymyxin B.

^a According to the criteria of Magiorakos *et al.* *Clin Microbiol Infect* 18:268-281, 2012

^b Phenotypic test for G3KL were performed using polypropylene (standard) and polystyrene 96-well plates

^c Overall, 33 out of 35 strains tested with polypropylene and 20 out of 35 strains tested with polystyrene plates had the same MIC and MBC values